Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
Full history for every metric is available with a Kvantra account
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 32 | 804 | 1,540 | 1,933 | 2,058 | 2,251 | 3,062 |
| Operating profit | CNY m | -466 | -368 | ||||||
| Net profit | CNY m | - | -875 | -616 | -574 | -267 | -382 | -418 | -17 |
| EPS reported | CNY | -1.66 | -1.80 | ||||||
| Operating cashflow per share | CNY | -0.78 | -0.82 | ||||||
| Capex per share | CNY | 0.55 | 0.59 | ||||||
| FCF per share | CNY | -1.33 | -1.41 | ||||||
| Free cash flow | CNY m | -307 | -330 | ||||||
| Net debt | CNY m | -4,559 | -4,485 | ||||||
| Book value equity | CNY m | 4,867 | 4,867 | ||||||
| Book value per share | CNY | 21.11 | 20.87 | ||||||
| Number of shares | m | 230.54 | 233.23 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 16.74 | 16.74 | ||||||
| P/S LTM | x | 39.59 | 36.18 | ||||||
| P/FCF LTM | x | -265.74 | -247.18 | ||||||
| EV/EBITDA LTM | x | -313.85 | -196.02 | ||||||
| EV/Sales LTM | x | 38.01 | 41.92 | ||||||
| Earnings Yield LTM | % | -0.47% | -0.43% | ||||||
| FCF Yield | % | -0.38% | -0.40% | ||||||
| Quality | |||||||||
| ROE | % | -7.85% | -10.25% | ||||||
| ROIC | % | -9.09% | -7.18% | ||||||
| Operating margin | % | -22.65% | -16.35% | ||||||
| Gross margin | % | +71.86% | +71.88% | ||||||
| FCF/Sales | % | -14.90% | -14.64% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +6.46% | +16.47% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.47 | -3.73 | ||||||
| Net Debt/EBITDA | x | 13.01 | 8.13 | ||||||
| EBIT/Net interest | x | -75.71 | 0.00 | ||||||
| Net debt/market cap | % | +0.12% | +0.10% | ||||||
| Net debt/Equity | x | -0.94 | -0.92 | ||||||
| Gross debt/equity | x | 0.02 | 0.02 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free